In a pioneering project aimed at revolutionizing the design of antibodies and antibody-like molecules through the power of AI, Lawrence Livermore National Laboratory (LLNL) is working to transform medical countermeasure development and biologics discovery. The project is part of an interagency agreement between the Advanced Research Projects Agency for Health and the Department of Energy.
Under the three-year DeNOVO project, LLNL and other institutions (including the University of California, San Francisco, the Institute for Protein Design at the University of Washington, Los Alamos National Laboratory and A-Alpha Bio) will apply high-performance computing and AI to push the boundaries of antibody design.
Technology Portfolio
